


# Arthritis Consumer Experts Arthritis Medications Report Card

Provincial Rankings 2020



# Table of Contents

INTRODUCTION ————— 1 - 2

PROVINCAL RANKINGS ————— 3 - 4



ONTARIO ————— 5 - 6



QUÉBEC ————— 7 - 8



ALBERTA ————— 9 - 10



BRITISH COLUMBIA ————— 11 - 12



SASKATCHEWAN ————— 13 - 14



MANITOBA ————— 15 - 16



NOVA SCOTIA ————— 17 - 18



NEW BRUNSWICK ————— 19 - 20



NEWFOUNDLAND AND LABRADOR — 21 - 22



PRINCE EDWARD ISLAND ——— 23 - 24



N.I.H.B. ————— 25 - 26



YUKON ————— 27 - 28

# Arthritis Medications Report Card

## Where does your province rank?

Advanced therapies such as biologics (originator and biosimilar) and targeted small molecule medications, deliver value both medically and socially. Used in a timely and appropriate fashion, these medications are life-changing; in some cases, life-saving. However, patients with inflammatory arthritis still have unmet medication needs. The gaps in treatment are a reflection of the fact that inflammatory arthritis is a complicated disease. It is a disease driven by many different biologic processes, so no single treatment is effective for every patient. In fact, a significant number of patients do not respond well or well enough to their initial, or second or third trialed, which underlines the need for continued discovery of other therapeutic targets.

Public drug plan policies at both the national, provincial, and territorial government levels are changing reimbursement access to treatment options for Canadians living with an inflammatory arthritis.

The Arthritis Consumer Experts (ACE) Arthritis Medications Report Card is designed to help Canadians evaluate where their province ranks in terms of providing reimbursement for medications approved for inflammatory arthritis such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis.

The ACE Arthritis Medications Report Card tracks advanced therapy disease modifying anti-rheumatic drugs (or DMARDs) used to treat the most common types of inflammatory arthritis:

- Biologic response modifier (originator or “boDMARD”)
- Biologic response modifier (biosimilar or “bsDMARD”)
- Targeted synthetic molecule (tsDMARD)

If your province doesn’t measure up, ACE encourages you to write and speak to your elected provincial or federal representative about the lack of equitable reimbursement access and patient/physician choice in treating inflammatory forms of arthritis.

## Definitions

Declined	The formulary does not reimburse patients prescribed this medication.
Listed—CBC	Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis.
Listed—ORC	The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.
N/A	(Not Applicable) No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.
Under Review	This drug has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.
CDR	The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec). ( <a href="http://cadth.ca/index.php/cdr">http://cadth.ca/index.php/cdr</a> )


**\* Note:** The Non-Insured Health Benefits (NHIB) program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada.

**Disclaimer:** The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.



# Arthritis Consumer Experts Arthritis Medications Report Card

Provincial Rankings 2020



# 1 ONTARIO

Improved reimbursement access to treatment options for patients living with an inflammatory arthritis in Canada’s largest province have contributed to Ontario retaining its top ranking on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the Ontario Drug Benefit Program. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Ontario has retained its top-ranking position due to the addition of six medications to its drug plan, meaning more patients have received affordable access to the medications they need.

- The additions to the drug plan over the past 12 months include:
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
  - rituximab (Truxima) for the treatment of rheumatoid arthritis
  - rituximab (Ruxience) for the treatment of rheumatoid arthritis
  - rituximab (Ruxience) for the treatment of vasculitis (Giant Cell Arteritis)
  - rituximab (Riximyo) for the treatment of rheumatoid arthritis
  - tofacitinib citrate (Xeljanz) for the treatment of rheumatoid arthritis, 11 mg oral tablet

- How can Ontario maintain and improve its position on the report card:
- Advance the medication review process of 14 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o rituximab (Riximyo) and rituximab (Truxima) for the treatment of vasculitis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Riximyo®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A



## 2 QUÉBEC

Over the past 12 months, pharmaceutical policy decisions have improved Quebec’s ranking on Arthritis Consumer Experts Arthritis Medications Report Card, providing better reimbursement access to treatment options for patients living with an inflammatory arthritis.

To be eligible for coverage, patients must meet criteria pre-defined by INESSS, Institut national d’excellence en santé et services sociaux. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Quebec has improved its ranking due to the addition of nine medications to its drug plan, meaning more patients have received affordable access to the medications they need.

The additions to the drug plan over the past 12 months include:

- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
- rituximab (Truxima) for the treatment of rheumatoid arthritis
- rituximab (Ruxience) for the treatment of rheumatoid arthritis
- ixekizumab (Taltz) for the treatment of ankylosing spondylitis
- infliximab (Avsola) for the treatment of rheumatoid arthritis
- infliximab (Avsola) for the treatment of ankylosing spondylitis
- infliximab (Avsola) for the treatment of psoriatic arthritis
- ixekizumab (Taltz) for the treatment of ankylosing spondylitis
- etanercept (Erelzi) for the treatment of psoriatic arthritis

How can Quebec improve its position on the report card:

- Advance the medication review process of 12 medications that treat types of inflammatory arthritis that are currently “under review.”
- Expand coverage for:
  - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
  - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
  - o rituximab (Rituxan), rituximab (Riximyo) and rituximab (Truxima) for the treatment of vasculitis
  - o rituximab (Riximyo) for the treatment of rheumatoid arthritis
  - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Ruxience®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Declined	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N.A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N.A	N.A	N.A	N.A	N.A	N.A	N.A

### 3 ALBERTA

The Alberta government has improved reimbursement for medications approved for inflammatory arthritis, which has led to Alberta retaining its positive third-place ranking on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the Alberta drug plan. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Alberta has retained its ranking position due to the addition of five medications to its drug plan, meaning more patients have received affordable access to the medications they need.

- The additions to the drug plan over the past 12 months include:
- rituximab (Truxima) for the treatment of rheumatoid arthritis
  - rituximab (Ruxience) for the treatment of rheumatoid arthritis
  - rituximab (Ruxience) for the treatment of vasculitis
  - rituximab (Riximyo) for the treatment of rheumatoid arthritis
  - tofacitinib citrate (Xeljanz) for the treatment of rheumatoid arthritis, 11 mg oral tablet

- How can Alberta improve its position on the report card:
- Advance the medication review process of 12 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o rituximab (Riximyo) and rituximab (Truxima) for the treatment of vasculitis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Riximyo®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

# 3 BRITISH COLUMBIA

Positive changes in the past year have allowed British Columbia (B.C.) to improve its ranking on Arthritis Consumer Experts Arthritis Medications Report Card, including increased reimbursement access to treatment options for patients living with an inflammatory arthritis.

To be eligible for coverage, patients must meet criteria pre-defined by B.C. PharmaCare. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

B.C. has improved its ranking position due to the addition of six medications to its drug plan, meaning more patients have received affordable access to the medications they need.

The additions to the drug plan over the past 12 months include:

- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
- rituximab (Truxima) for the treatment of rheumatoid arthritis
- rituximab (Ruxience) for the treatment of rheumatoid arthritis
- rituximab (Riximyo) for the treatment of rheumatoid arthritis
- rituximab (Truxima) for the treatment of vasculitis
- rituximab (Ruxience) for the treatment of vasculitis

How can B.C. improve its position on the report card:

- Advance the medication review process of 11 medications that treat types of inflammatory arthritis that are currently “under review.”
- Expand coverage for:
  - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
  - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
  - o rituximab (Riximyo) for the treatment of vasculitis
  - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Riximyo®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A



# 5 SASKATCHEWAN

Pharmaceutical policy decisions in Saskatchewan have reduced reimbursement access to treatment options for patients living with an inflammatory arthritis and had a negative impact on the ranking Saskatchewan receives on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the Saskatchewan Drug Plan. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Saskatchewan has dropped in ranking over the past 12 months due to the relative low number of new additions to the Saskatchewan Drug Plan, reducing affordable access to medications patients need.

- The additions to the drug plan over the past 12 months include:
- tofacitinib citrate (Xeljanz) for the treatment of rheumatoid arthritis, 11 mg oral tablet
  - tocilizumab (Actemra) for the treatment of vasculitis (Giant Cell Arteritis)

- How can Saskatchewan improve its position on the report card:
- Advance the medication review process of 15 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

# 6 MANITOBA

Manitoba’s Pharmacare Program policy decisions have improved reimbursement access to treatment options for patients living with an inflammatory arthritis and have contributed to Manitoba retaining its ranking on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the Manitoba Pharmacare Program. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Manitoba has retained its ranking position due to the addition of four medications to its drug plan, meaning more patients have received affordable access to the medications they need.

The additions to the drug plan over the past 12 months include:

- etanercept (Erelzi) for the treatment of psoriatic arthritis
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
- tofacitinib citrate (Xeljanz) for the treatment of rheumatoid arthritis, 11 mg oral tablet
- rituximab (Truxima) for the treatment of rheumatoid arthritis

How can Manitoba improve its position on the report card:

- Advance the medication review process of 20 medications that treat types of inflammatory arthritis that are currently “under review.”
- Expand coverage for:
  - o abatacept (Orencia) and etanercept (Enbrel) for the treatment of juvenile idiopathic arthritis
  - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
  - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
  - o rituximab (Truxima) for the treatment of vasculitis
  - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

# 6 NOVA SCOTIA

Nova Scotia has added the second most medications among Canadian public drug plans for patients living with an inflammatory arthritis, enabling Nova Scotia to improve its ranking on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by Nova Scotia Pharmacare. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Nova Scotia has improved its ranking position due to the addition of six medications to its drug plan, meaning more patients have received affordable access to the medications they need.

- The additions to the drug plan over the past 12 months include:
- infliximab (Renflexis) for the treatment of rheumatoid arthritis
  - infliximab (Renflexis) for the treatment of ankylosing spondylitis
  - infliximab (Renflexis) for the treatment of psoriatic arthritis
  - tocilizumab (Actemra) for the treatment of vasculitis (Giant Cell Arteritis)
  - rituximab (Truxima) for the treatment of rheumatoid arthritis
  - etanercept (Erelzi) for the treatment of psoriatic arthritis

- How can Nova Scotia improve its position on the report card:
- Advance the medication review process of 20 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A



# 6 NEW BRUNSWICK

Reimbursement coverage decisions for medications to treat patients living with an inflammatory arthritis have improved New Brunswick’s ranking on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the New Brunswick Drug Plan. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

New Brunswick has improved its ranking position due to the addition of six medications to its drug plan, meaning more patients have received affordable access to the medications they need.

- The additions to the drug plan over the past 12 months include:
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
  - tocilizumab (Actemra) for the treatment of vasculitis (Giant Cell Arteritis)
  - tofacitinib citrate (Xeljanz) for the treatment of rheumatoid arthritis, 11 mg oral tablet
  - infliximab (Renflexis) for the treatment of rheumatoid arthritis
  - infliximab (Renflexis) for the treatment of ankylosing spondylitis
  - infliximab (Renflexis) for the treatment of psoriatic arthritis

- How can New Brunswick improve its position on the report card:
- Advance the medication review process of 16 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

# 9 NEWFOUNDLAND AND LABRADOR

The high number of medications under review on the Newfoundland and Labrador Prescription Drug Program have reduced reimbursement access to treatment options for patients and had a negative impact on the ranking Newfoundland and Labrador receives on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the Newfoundland and Labrador Prescription Drug Program. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Newfoundland and Labrador has a low ranking over the past 12 months due to the relative low number of new additions and the number of medications “under review” on the Newfoundland and Labrador Prescription Drug Program, reducing affordable access to medications patients need.

- The additions to the drug plan over the past 12 months include:
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
  - tocilizumab (Actemra) for the treatment of vasculitis (Giant Cell Arteritis)

- How can Newfoundland and Labrador improve its position on the report card:
- Advance the medication review process of 20 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Declined	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

# 10 PRINCE EDWARD ISLAND

Prince Edward Island (PEI) Pharmacare policy decisions have reduced reimbursement access to treatment options for patients and had a negative impact on the ranking PEI receives on Arthritis Consumer Experts Arthritis Medications Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by PEI Pharmacare. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

PEI has a low ranking over the past 12 months due to the relative low number of new additions and the high number of medications “under review” on PEI Pharmacare, reducing affordable access to medications patients need.

The additions to the drug plan over the past 12 months include:

- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
- etanercept (Erelzi) for the treatment of psoriatic arthritis

How can PEI improve their position on the report card:

- Advance the medication review process of 22 medications that treat types of inflammatory arthritis that are currently “under review.”
- Expand coverage for:
  - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
  - o etanercept (Erelzi) for the treatment of juvenile idiopathic arthritis
  - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
  - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Under Review	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A



# 11 NON-INSURED HEALTH BENEFITS FOR FIRST NATIONS (NIHB)

Reimbursement access to treatment options for patients under the NIHB program continues to be a challenge over the past year and had a negative impact on the ranking NIHB receives in Arthritis Consumer Experts Arthritis Medication Report Card.

To be eligible for coverage, patients must meet criteria pre-defined by the NIHB program. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

NIHB has a low ranking over the past 12 months due to the relative low number of new additions and the high number of medications “under review” on the NIHB program, reducing affordable access to medications patients need.

- The additions to the drug plan over the past 12 months include:
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
  - etanercept (Erelzi) for the treatment of psoriatic arthritis

- How can NIHB improve its position on the report card:
- Advance the medication review process of 22 medications that treat types of inflammatory arthritis that are currently “under review.”
  - Expand coverage for:
    - o etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis and psoriatic arthritis
    - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
    - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Under Review	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Declined	N/A	N/A	Declined	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N.A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N.A	N.A	N.A	N.A	N.A	N.A	N.A



# 12 YUKON

With a number of additions to its formulary, the Yukon has improved reimbursement access to treatment options for patients living with an inflammatory arthritis. However, the Yukon still ranks relatively low on Arthritis Consumer Experts Arthritis Medication Report Card when compared to the number of medications listed on other provincial drug plans.

To be eligible for coverage, patients must meet criteria pre-defined by the Yukon Drug Formulary. Actual coverage depends on the rules of the patients’ drug plan, including any annual deductible requirement.

Yukon has a low ranking over the past 12 months due to the high number of medications “under review” on the Yukon Drug Formulary, reducing affordable access to medications patients need.

The additions to the drug plan over the past 12 months include:

- abatacept (Orencia) for the treatment of rheumatoid arthritis
- sarilumab (Kevzara) for the treatment of rheumatoid arthritis
- etanercept (Brenzys) for the treatment of psoriatic arthritis
- etanercept (Erelzi) for the treatment of psoriatic arthritis
- tocilizumab (Actemra) for the treatment of juvenile idiopathic arthritis
- tocilizumab (Actemra) for the treatment of vasculitis (Giant Cell Arteritis)
- rituximab (Truxima) for the treatment of rheumatoid arthritis

How can the Yukon improve its position on the report card:

- Advance the medication review process of 26 medications that treat types of inflammatory arthritis that are currently “under review.”
- Expand coverage for:
  - o abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and etanercept (Brenzys) for the treatment of juvenile idiopathic arthritis
  - o golimumab (Simponi) for the treatment of non-radiographic axial spondyloarthritis
  - o rituximab (Rituxan) and rituximab (Truxima) for the treatment of vasculitis
  - o tofacitinib citrate (Xeljanz) for the treatment of psoriatic arthritis



Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Avsola®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Renflexis®, bsDMARD)	Under Review	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
ixekizumab (Taltz®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
rituximab (Rituxan®, boDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Ruxience®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Riximyo®, bsDMARD)	Under Review	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
rituximab (Truxima®, bsDMARD)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	Listed—CBC	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
baricitinib (Olumiant®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
upadacitinib (Rinvoq®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A